IDEXX Laboratories Stock Price, News & Analysis (NASDAQ:IDXX)

$187.61 +3.75 (+2.04 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$187.61
Today's Range$183.48 - $187.63
52-Week Range$141.02 - $198.73
Volume461,340 shs
Average Volume669,459 shs
Market Capitalization$16.02 billion
P/E Ratio63.81
Dividend YieldN/A
Beta0.58

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Veterinary Medical Equipment & Supplies
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Debt-to-Equity Ratio-11.26%
Current Ratio0.97%
Quick Ratio0.80%

Price-To-Earnings

Trailing P/E Ratio63.812925170068
Forward P/E Ratio45.87
P/E Growth2.26

Sales & Book Value

Annual Sales$1.97 billion
Price / Sales8.30
Cash Flow$4.41 per share
Price / Cash42.50
Book Value($0.62) per share
Price / Book-302.60

Profitability

Trailing EPS$2.94
Net Income$263.14 million
Net Margins13.36%
Return on Equity-432.19%
Return on Assets17.19%

Miscellaneous

Employees7,365
Outstanding Shares87,120,000

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its Board of Directors has initiated a share buyback program on Sunday, June 4th 2017, which permits the company to repurchase 3,000,000 shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Thursday, February, 1st. The company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.73 by $0.04. The business earned $506 million during the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The business's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.58 EPS. View IDEXX Laboratories' Earnings History.

When will IDEXX Laboratories make its next earnings announcement?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $4.04-4.18 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.72. The company issued revenue guidance of $2.205-2.245 billion, compared to the consensus revenue estimate of $2.16 billion.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2018?

6 brokers have issued 1-year price objectives for IDEXX Laboratories' shares. Their predictions range from $118.00 to $220.00. On average, they expect IDEXX Laboratories' stock price to reach $190.67 in the next year. View Analyst Ratings for IDEXX Laboratories.

What are Wall Street analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "IDEXX exited the fourth quarter on a solid note. The company continues to demonstrate solid growth globally on consistent consumable revenue gains. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX recently commercially launched Catalyst SDMA Test in North America. Solid organic revenue growth along with a raised guidance for 2018 buoys optimism. Moreover, over the past year, IDEXX has been trading above the broader industry. However, its high dependence on third-party distributors and intense competition continue to pose threats. The stock’s overvaluation is also a concern." (2/5/2018)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:

  • Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer (Age 60)
  • Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer (Age 54)
  • Giovani Twigge, Chief Human Resource Officer, Corporate Vice President (Age 53)
  • Jay Mazelsky, Executive Vice President (Age 56)
  • Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary (Age 58)
  • William T. End, Lead Independent Director (Age 69)
  • Bruce L Claflin, Independent Director (Age 65)
  • Stuart M. Essig Ph.D., Independent Director (Age 55)
  • Rebecca M. Henderson Ph.D., Independent Director (Age 56)
  • Daniel M. Junius, Independent Director (Age 64)

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.90%), Bamco Inc. NY (5.39%), Renaissance Technologies LLC (2.16%), Arrowstreet Capital Limited Partnership (1.44%), Bank of New York Mellon Corp (1.31%) and Old Mutual Global Investors UK Ltd. (1.14%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Lazard Asset Management LLC, Guggenheim Capital LLC, Allianz Asset Management GmbH, Two Sigma Investments LP, AXA, First Trust Advisors LP and APG Asset Management N.V.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?

IDEXX Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Renaissance Technologies LLC, Carillon Tower Advisers Inc., American Century Companies Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp, Old Mutual Global Investors UK Ltd. and TCW Group Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDEXX Laboratories stock can currently be purchased for approximately $187.61.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $16.02 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $2.94 on an earnings per share basis. IDEXX Laboratories employs 7,365 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (IDXX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IDEXX Laboratories (NASDAQ:IDXX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldHold
Consensus Rating Score: 2.672.432.332.33
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $190.67$176.33$171.60$171.60
Price Target Upside: 0.96% downside1.79% upside4.36% upside12.29% upside

IDEXX Laboratories (NASDAQ:IDXX) Consensus Price Target History

Price Target History for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ:IDXX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018Bank of AmericaBoost Price TargetBuy -> Buy$200.00 -> $220.00HighView Rating Details
2/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$211.00HighView Rating Details
1/29/2018Canaccord GenuityReiterated RatingBuy$210.00LowView Rating Details
12/8/2017AegisReiterated RatingSellLowView Rating Details
10/24/2017Stifel NicolausReiterated RatingBuy$185.00N/AView Rating Details
7/28/2017CL KingUpgradeNeutral -> Buy$200.00MediumView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

IDEXX Laboratories (NASDAQ:IDXX) Earnings History and Estimates Chart

Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ IDXX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018$0.90N/AView Earnings Details
2/1/2018Q4 2017$0.73$0.77$490.51 million$506.00 millionViewN/AView Earnings Details
10/31/2017Q3 2017$0.74$0.79$492.94 million$492.00 millionViewN/AView Earnings Details
8/1/2017Q2 2017$0.85$0.95$502.44 million$508.90 millionViewListenView Earnings Details
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
10/22/2010Q3 2010$0.28$0.29ViewN/AView Earnings Details
7/23/2010Q2 2010$0.31$0.31ViewN/AView Earnings Details
4/23/2010Q1 2010$0.25$0.28ViewN/AView Earnings Details
1/29/2010Q4 2009$0.23$0.26ViewN/AView Earnings Details
10/23/2009Q3 2009$0.23$0.26ViewN/AView Earnings Details
7/24/2009Q2 2009$0.27$0.28ViewN/AView Earnings Details
4/24/2009Q1 2009$0.19$0.22ViewN/AView Earnings Details
1/30/2009Q4 2008$0.21$0.22ViewN/AView Earnings Details
10/24/2008Q3 2008$0.20$0.21ViewN/AView Earnings Details
7/25/2008Q2 2008$0.28$0.32ViewN/AView Earnings Details
4/25/2008Q1 2008$0.20$0.21ViewN/AView Earnings Details
1/25/2008Q4 2007$0.20$0.20ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

IDEXX Laboratories (NASDAQ:IDXX) Earnings Estimates

2018 EPS Consensus Estimate: $3.89
2019 EPS Consensus Estimate: $4.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.89$0.90$0.90
Q2 20182$1.09$1.18$1.14
Q3 20182$0.98$0.98$0.98
Q4 20182$0.77$0.99$0.88
Q1 20191$1.01$1.01$1.01
Q2 20191$1.40$1.40$1.40
Q3 20191$1.19$1.19$1.19
Q4 20191$1.15$1.15$1.15
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for IDEXX Laboratories (NASDAQ:IDXX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

IDEXX Laboratories (NASDAQ IDXX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.77%
Institutional Ownership Percentage: 86.02%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ IDXX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2018William T EndDirectorSell4,000$184.48$737,920.0041,256View SEC Filing  
2/14/2018Lawrence D KingsleyDirectorBuy1,000$178.05$178,050.004,558View SEC Filing  
2/8/2018Jonathan W AyersChairmanSell22,000$177.52$3,905,440.001,077,112View SEC Filing  
2/7/2018Bruce L ClaflinDirectorBuy1,000$179.58$179,580.001,000View SEC Filing  
2/6/2018Jonathan W AyersChairmanSell36,000$179.28$6,454,080.001,077,112View SEC Filing  
2/5/2018Brian P MckeonVPSell6,602$181.36$1,197,338.7247,040View SEC Filing  
1/11/2018Jonathan W AyersCEOSell2,160$167.03$360,784.801,077,112View SEC Filing  
1/9/2018Jonathan W AyersCEOSell18,000$165.15$2,972,700.001,077,112View SEC Filing  
11/30/2017Giovani TwiggeInsiderSell2,000$156.07$312,140.00View SEC Filing  
11/16/2017Jonathan W AyersCEOSell18,000$153.61$2,764,980.001,064,573View SEC Filing  
11/14/2017Jonathan W AyersCEOSell18,000$148.35$2,670,300.001,064,573View SEC Filing  
11/7/2017Jonathan W AyersChairmanSell54,000$151.32$8,171,280.001,064,573View SEC Filing  
11/3/2017Jonathan W AyersCEOSell18,000$153.75$2,767,500.001,064,573View SEC Filing  
8/28/2017Jonathan W AyersChairmanSell13,000$150.79$1,960,270.001,044,034View SEC Filing  
8/23/2017Rebecca M HendersonDirectorSell5,156$153.29$790,363.2417,274View SEC Filing  
8/22/2017Rebecca M HendersonDirectorSell2,578$152.86$394,073.0817,274View SEC Filing  
8/16/2017Jonathan W AyersChairmanSell58,000$155.00$8,990,000.001,043,034View SEC Filing  
8/15/2017Jonathan W AyersCEOSell20,000$154.62$3,092,400.001,043,034View SEC Filing  
8/14/2017Jonathan W AyersCEOSell18,000$154.91$2,788,380.001,043,034View SEC Filing  
8/9/2017Jonathan W AyersChairmanSell17,000$154.54$2,627,180.001,039,034View SEC Filing  
8/8/2017Jonathan W. AyersChairmanSell18,000$155.22$2,793,960.00View SEC Filing  
8/3/2017Lawrence D KingsleyDirectorBuy2,000$151.76$303,520.003,344View SEC Filing  
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.001,032,994View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.0045,256View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.001,024,994View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.0021,552View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.001,135View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00995,947View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.3645,235View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.005,495View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.481,001,043View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.161,001,043View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.0032,783View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.0048,654View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.3216,678View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.8813,484View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.0053,564View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.8863,578View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.0040,011View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.0822,298View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.1032,461View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.0022,048View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.0021,450View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.0021,793View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.2439,654View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.0022,593View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.005,000View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.0011,976View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24389,665View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62377,211View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.001,000View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08365,389View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.003,000View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.8011,566View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.528,989View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

IDEXX Laboratories (NASDAQ IDXX) News Headlines

Source:
DateHeadline
Norinchukin Bank The Purchases 4,276 Shares of IDEXX Laboratories, Inc. (IDXX)Norinchukin Bank The Purchases 4,276 Shares of IDEXX Laboratories, Inc. (IDXX)
www.americanbankingnews.com - February 24 at 2:18 PM
IDEXX Laboratories, Inc. (IDXX) Stake Boosted by Wells Fargo & Company MNIDEXX Laboratories, Inc. (IDXX) Stake Boosted by Wells Fargo & Company MN
www.americanbankingnews.com - February 24 at 5:56 AM
IDEXX Laboratories, Inc. (IDXX) Director William T. End Sells 4,000 SharesIDEXX Laboratories, Inc. (IDXX) Director William T. End Sells 4,000 Shares
www.americanbankingnews.com - February 23 at 6:24 PM
Zacks: Analysts Anticipate IDEXX Laboratories, Inc. (IDXX) to Post $0.93 Earnings Per ShareZacks: Analysts Anticipate IDEXX Laboratories, Inc. (IDXX) to Post $0.93 Earnings Per Share
www.americanbankingnews.com - February 22 at 9:26 AM
Insider Buying: IDEXX Laboratories, Inc. (IDXX) Director Acquires 1,000 Shares of StockInsider Buying: IDEXX Laboratories, Inc. (IDXX) Director Acquires 1,000 Shares of Stock
www.americanbankingnews.com - February 16 at 10:02 PM
IDEXX Laboratories Inc (IDXX) Files 10-K for the Fiscal Year Ended on December 31, 2017IDEXX Laboratories Inc (IDXX) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 16 at 5:25 PM
Idexx Laboratories: Take The Money And Run - Seeking AlphaIdexx Laboratories: Take The Money And Run - Seeking Alpha
seekingalpha.com - February 16 at 8:08 AM
IDEXX Laboratories to Present at Two ConferencesIDEXX Laboratories to Present at Two Conferences
finance.yahoo.com - February 15 at 5:28 PM
BidaskClub Downgrades IDEXX Laboratories (IDXX) to BuyBidaskClub Downgrades IDEXX Laboratories (IDXX) to Buy
www.americanbankingnews.com - February 11 at 8:54 AM
IDEXX Laboratories, Inc. (IDXX) Given Average Recommendation of "Buy" by AnalystsIDEXX Laboratories, Inc. (IDXX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 10 at 1:38 PM
IDEXX Laboratories, Inc. (IDXX) Chairman Sells $3,905,440.00 in StockIDEXX Laboratories, Inc. (IDXX) Chairman Sells $3,905,440.00 in Stock
www.americanbankingnews.com - February 9 at 9:28 PM
Idexx Laboratories Inc (IDXX) Chairman, President & CEO Jonathan W Ayers Sold $6. ...Idexx Laboratories Inc (IDXX) Chairman, President & CEO Jonathan W Ayers Sold $6. ...
finance.yahoo.com - February 8 at 8:03 AM
IDEXX Laboratories, Inc. (IDXX) Chairman Sells $6,454,080.00 in StockIDEXX Laboratories, Inc. (IDXX) Chairman Sells $6,454,080.00 in Stock
www.americanbankingnews.com - February 8 at 12:10 AM
IDEXX Laboratories, Inc. (IDXX) VP Brian P. Mckeon Sells 6,602 SharesIDEXX Laboratories, Inc. (IDXX) VP Brian P. Mckeon Sells 6,602 Shares
www.americanbankingnews.com - February 8 at 12:10 AM
$525.03 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter$525.03 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - February 7 at 5:48 AM
IDEXX Laboratories Strong on CAG Business Amid Currency Woes - NasdaqIDEXX Laboratories Strong on CAG Business Amid Currency Woes - Nasdaq
www.nasdaq.com - February 6 at 3:35 PM
IDEXX Laboratories Strong on CAG Business Amid Currency WoesIDEXX Laboratories Strong on CAG Business Amid Currency Woes
www.zacks.com - February 6 at 8:16 AM
IDEXX Laboratories Separates From the PackIDEXX Laboratories Separates From the Pack
www.fool.com - February 5 at 4:46 PM
IDEXX Laboratories (IDXX) Upgraded to Strong-Buy by Zacks Investment ResearchIDEXX Laboratories (IDXX) Upgraded to Strong-Buy by Zacks Investment Research
www.americanbankingnews.com - February 5 at 3:52 PM
Zacks: Brokerages Anticipate IDEXX Laboratories, Inc. (IDXX) to Post $0.93 EPSZacks: Brokerages Anticipate IDEXX Laboratories, Inc. (IDXX) to Post $0.93 EPS
www.americanbankingnews.com - February 5 at 9:46 AM
Equities Analysts Set Expectations for IDEXX Laboratories, Inc.s FY2018 Earnings (IDXX)Equities Analysts Set Expectations for IDEXX Laboratories, Inc.'s FY2018 Earnings (IDXX)
www.americanbankingnews.com - February 5 at 5:46 AM
Analysts Issue Forecasts for IDEXX Laboratories, Inc.s Q1 2018 Earnings (IDXX)Analysts Issue Forecasts for IDEXX Laboratories, Inc.'s Q1 2018 Earnings (IDXX)
www.americanbankingnews.com - February 5 at 2:10 AM
Bank of America Boosts IDEXX Laboratories (IDXX) Price Target to $220.00Bank of America Boosts IDEXX Laboratories (IDXX) Price Target to $220.00
www.americanbankingnews.com - February 2 at 9:54 PM
IDEXX Laboratories, Inc. (IDXX) to Post Q1 2018 Earnings of $0.90 Per Share, William Blair ForecastsIDEXX Laboratories, Inc. (IDXX) to Post Q1 2018 Earnings of $0.90 Per Share, William Blair Forecasts
www.americanbankingnews.com - February 2 at 8:48 AM
IDEXX Laboratories Announces Fourth Quarter and Full Year 2017 Results - PR Newswire (press release)IDEXX Laboratories Announces Fourth Quarter and Full Year 2017 Results - PR Newswire (press release)
www.prnewswire.com - February 2 at 8:10 AM
IDEXX Laboratories (IDXX) PT Raised to $211.00IDEXX Laboratories (IDXX) PT Raised to $211.00
www.americanbankingnews.com - February 1 at 4:58 PM
IDEXX Laboratories (IDXX) Releases Quarterly  Earnings Results, Beats Estimates By $0.04 EPSIDEXX Laboratories (IDXX) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - February 1 at 9:52 AM
IDEXX Laboratories (IDXX) Issues FY18 Earnings GuidanceIDEXX Laboratories (IDXX) Issues FY18 Earnings Guidance
www.americanbankingnews.com - February 1 at 9:31 AM
IDEXX Laboratories (IDXX) Beats on Q4 Revenues, View UpIDEXX Laboratories (IDXX) Beats on Q4 Revenues, View Up
www.zacks.com - February 1 at 8:28 AM
IDEXX Laboratories Inc Reports Drop In Q4 Bottom LineIDEXX Laboratories Inc Reports Drop In Q4 Bottom Line
www.nasdaq.com - February 1 at 8:28 AM
Idexx beats Street 4Q forecastsIdexx beats Street 4Q forecasts
finance.yahoo.com - February 1 at 8:28 AM
IDEXX Laboratories, Inc. to Host Earnings CallIDEXX Laboratories, Inc. to Host Earnings Call
finance.yahoo.com - February 1 at 8:28 AM
IDEXX Laboratories Announces Fourth Quarter and Full Year 2017 ResultsIDEXX Laboratories Announces Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 1 at 8:28 AM
IDEXX Laboratories (IDXX) Cut to "Hold" at Zacks Investment ResearchIDEXX Laboratories (IDXX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 31 at 1:48 PM
Pre-Market Technical Scan on Diagnostic Substances Equities -- Advanced Accelerator Applications, AMAG Pharma, DBV Technologies, and IDEXX LabsPre-Market Technical Scan on Diagnostic Substances Equities -- Advanced Accelerator Applications, AMAG Pharma, DBV Technologies, and IDEXX Labs
www.bizjournals.com - January 31 at 8:28 AM
IDEXX Laboratories (IDXX) Receives Buy Rating from Canaccord GenuityIDEXX Laboratories (IDXX) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - January 29 at 1:46 PM
IDEXX Laboratories (IDXX) to Release Earnings on ThursdayIDEXX Laboratories (IDXX) to Release Earnings on Thursday
www.americanbankingnews.com - January 25 at 2:02 AM
Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength? - NasdaqCan IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength? - Nasdaq
www.nasdaq.com - January 24 at 3:42 PM
Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?
finance.yahoo.com - January 23 at 4:10 PM
$491.02 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter$491.02 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - January 21 at 8:08 AM
IDEXX Laboratories to Release 2017 Fourth Quarter and Full-Year Financial Results - PR Newswire (press release)IDEXX Laboratories to Release 2017 Fourth Quarter and Full-Year Financial Results - PR Newswire (press release)
www.prnewswire.com - January 19 at 8:21 AM
IDEXX Laboratories to Release 2017 Fourth Quarter and Full-Year Financial ResultsIDEXX Laboratories to Release 2017 Fourth Quarter and Full-Year Financial Results
finance.yahoo.com - January 18 at 7:01 PM
Stocks With Rising Relative Strength: Idexx LaboratoriesStocks With Rising Relative Strength: Idexx Laboratories
finance.yahoo.com - January 17 at 11:20 AM
IDEXX Laboratories, Inc. (IDXX) Given Consensus Recommendation of "Hold" by BrokeragesIDEXX Laboratories, Inc. (IDXX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 16 at 1:40 PM
IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder - NasdaqIDEXX Launches Catalyst SDMA for Veterinary Renal Disorder - Nasdaq
www.nasdaq.com - January 15 at 3:37 PM
IDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 2,160 SharesIDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 2,160 Shares
www.americanbankingnews.com - January 11 at 6:58 PM
Jonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) StockJonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock
www.americanbankingnews.com - January 11 at 6:38 PM
IDEXX to Introduce Applied BioCodes Innovative Multiplex Technology Across Global Reference Laboratory Network - PR Newswire (press release)IDEXX to Introduce Applied BioCode's Innovative Multiplex Technology Across Global Reference Laboratory Network - PR Newswire (press release)
www.prnewswire.com - January 9 at 3:37 PM
IDEXX Launches SDMA in the Point of Care with IDEXX Catalyst® SDMA Test - PR Newswire (press release)IDEXX Launches SDMA in the Point of Care with IDEXX Catalyst® SDMA Test - PR Newswire (press release)
www.prnewswire.com - January 9 at 3:37 PM
IDEXX Launches SDMA in the Point of Care with IDEXX Catalyst® SDMA TestIDEXX Launches SDMA in the Point of Care with IDEXX Catalyst® SDMA Test
finance.yahoo.com - January 8 at 8:52 AM

SEC Filings

IDEXX Laboratories (NASDAQ:IDXX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IDEXX Laboratories (NASDAQ:IDXX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IDEXX Laboratories (NASDAQ IDXX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.